H Marijke Van Den Berg

List of Publications by Year
in descending order

50 papers	4,698 citations	279798 23 h-index	223800 46 g-index
50 all docs	50 docs citations	50 times ranked	2281 citing authors

#	Article	IF	Citations
1	WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia, 2020, 26, 1-158.	2.1	915
2	ITI Treatment is not First-Choice Treatment in Children with Hemophilia A and Low-Responding Inhibitors: Evidence from a PedNet Study. Thrombosis and Haemostasis, 2020, 120, 1166-1172.	3.4	7
3	Inhibitor development in previously untreated patients with severe haemophilia: A comparison of included patients and outcomes between a clinical study and a registryâ€based study. Haemophilia, 2020, 26, 809-816.	2.1	2
4	Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. Blood, 2019, 134, 317-320.	1.4	71
5	Clinical trials and registries in haemophilia: Opponents or collaborators? Comparison of PUP data derived from different data sources. Haemophilia, 2018, 24, 420-428.	2.1	6
6	World bleeding disorders registry: The pilot study. Haemophilia, 2018, 24, e113-e116.	2.1	13
7	Vaccinations are not associated with inhibitor development in boys with severe haemophilia A. Haemophilia, 2018, 24, 283-290.	2.1	24
8	International collaboration is needed to reduce the risk for inhibitors in <scp>PUP</scp>s with severe haemophilia A. Haemophilia, 2018, 24, e242-e243.	2.1	0
9	From treatment to prevention of bleeds: what more evidence do we need?. Haemophilia, 2017, 23, 494-496.	2.1	1
10	Plasma products do not solve the inhibitor problem. Haemophilia, 2017, 23, 346-347.	2.1	9
11	Establishing the appropriate primary endpoint in haemophilia gene therapy pivotal studies. Haemophilia, 2017, 23, 643-644.	2.1	18
12	Registries supporting new drug applications. Pharmacoepidemiology and Drug Safety, 2017, 26, 1451-1457.	1.9	23
13	Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors. Thrombosis and Haemostasis, 2017, 117, 2274-2282.	3.4	13
14	Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors. Thrombosis and Haemostasis, 2016, 115, 729-737.	3.4	18
15	Reply to the letter of O'Mahoney et al.. Haemophilia, 2016, 22, e209-11.	2.1	0
16	Preventing bleeds by treatment: new era for haemophilia changing the paradigm. Haemophilia, 2016, 22, 9-13.	2.1	8
17	Haemophilia registries to complement clinical trial data: a pious hope or an urgent necessity?. Haemophilia, 2016, 22, 647-650.	2.1	4
18	Standardizing patient outcomes measurement to improve haemophilia care. Haemophilia, 2016, 22, 651-653.	2.1	7

#	Article	IF	Citations
19	Different impact of factor VIII products on inhibitor development?. Thrombosis Journal, 2016, 14, 31.	2.1	10
20	Validation of the prediction model for inhibitor development in PUPs with severe haemophilia A. Haemophilia, 2016, 22, e116-e118.	2.1	1
21	Assessment of Clotting Factor Concentratesâ€"Pivotal Studies and Long-Term Requirements. Seminars in Thrombosis and Hemostasis, 2015, 41, 855-859.	2.7	5
22	Assessments of outcome in haemophilia â€“ what is the added value of <scp>QoL</scp> tools?. Haemophilia, 2015, 21, 430-435.	2.1	25
23	The growing number of hemophilia registries: Quantity vs. quality. Clinical Pharmacology and Therapeutics, 2015, 97, 492-501.	4.7	16
24	Improved prediction of inhibitor development in previously untreated patients with severe haemophilia A. Haemophilia, 2015, 21, 227-233.	2.1	18
25	Epidemiological aspects of inhibitor development redefine the clinical importance of inhibitors. Haemophilia, 2014, 20, 76-79.	2.1	15
26	Definitions in hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2014, 12, 1935-1939.	3.8	530
27	Prospective observational cohort studies for studying rare diseases: the European PedNet Haemophilia Registry. Haemophilia, 2014, 20, e280-6.	2.1	60
28	Factor VIII Products and Inhibitor Development in Severe Hemophilia A. New England Journal of Medicine, 2013, 368, 231-239.	27.0	383
29	Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood, 2013, 122, 1129-1136.	1.4	200
30	Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood, 2013, 121, 4046-4055.	1.4	287
31	F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood, 2012, 119, 2922-2934.	1.4	305
32	Clinical prediction models for inhibitor development in severe hemophilia A. Journal of Thrombosis and Haemostasis, 2009, 7, 98-102.	3.8	18
33	Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice. Journal of Thrombosis and Haemostasis, 2008, 6, 2048-2054.	3.8	74
34	Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood, 2007, 109, 4648-4654.	1.4	449
35	Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood, 2007, 109, 4693-4697.	1.4	220
36	Cyclosporin A can achieve immune tolerance in a patient with severe haemophilia B and refractory inhibitors. Haemophilia, 2007, 13, 111-114.	2.1	27

#	Article	IF	Citations
37	Phenotypic heterogeneity in severe hemophilia. Journal of Thrombosis and Haemostasis, 2007, 5, 151-156.	3.8	106
38	Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. Journal of Thrombosis and Haemostasis, 2007, 5, 1383-1390.	3.8	134
39	Cysteine-mutations in von Willebrand factor associated with increased clearance. Journal of Thrombosis and Haemostasis, 2005, 3, 2228-2237.	3.8	80
40	Effects of haemophilic arthropathy on health-related quality of life and socio-economic parameters. Haemophilia, 2005, 11, 43-48.	2.1	91
41	Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia, 2005, 11, 438-443.	2.1	125
42	Functional consequences of haemophilia in adults: the development of the Haemophilia Activities List. Haemophilia, 2004, 10, 565-571.	2.1	105
43	Variability in Bleeding Pattern of Severe Hemophilia.. Blood, 2004, 104, 3094-3094.	1.4	4
44	Incidence and Outcome of Discontinuation of Prophylactic Treatment among Young Adults with Severe Hemophilia.. Blood, 2004, 104, 3086-3086.	1.4	5
45	Comparing outcomes of different treatment regimens for severe haemophilia. Haemophilia, 2003, 9, 27-31.	2.1	44
46	Prophylaxis for Severe Hemophilia: Experience from Europe and the United States. Seminars in Thrombosis and Hemostasis, 2003, 29, 049-054.	2.7	25
47	Association between joint bleeds and pettersson scores in severe haemophilia. Acta Radiologica, 2002, 43, 528-532.	1.1	31
48	Longâ€term outcome of individualized prophylactic treatment of children with severe haemophilia. British Journal of Haematology, 2001, 112, 561-565.	2.5	166
49	Product choice and haemophilia treatment in the Netherlands. Haemophilia, 2001, 7, 96-98.	2.1	0
50	Improvement of patient education and information: development of a patientâ€™s information dossier. Haemophilia, 2001, 7, 397-400.	2.1	0